Close Menu

NEW YORK – Quest Diagnostics received on Tuesday Emergency Use Authorization from the US Food and Drug Administration for its SARS-CoV-2 rRT PCR test.

The issuance allows Quest to provide the test for individuals suspected by their healthcare providers of having COVID-19.

On Saturday, the company said that between the capacity provided by its own test as well as other authorized in vitro diagnostic SARS-CoV-2 test kits, it expected to be able to perform roughly 10,000 tests a day by the end of this week and roughly 20,000 tests per day by the end of March.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Jul
14

This webinar will describe a rapid metagenomics assay under development for human pathogens, including the SARS-CoV-2 coronavirus.

Jul
15
Sponsored by
LGC SeraCare Life Sciences

Cancer immunotherapy is an exciting new advance for the successful treatment of many forms of metastatic cancer.

Jul
23

This webinar will discuss a study that set to assess the efficacy and safety of osimertinib in EGFR T790M positive non-small cell lung cancer (NSCLC) patients identified by using plasma sample and cobas EGFR Mutation test v2. This is the first prospective study to use liquid biopsy upfront to evaluate osimertinib efficacy.